In this week's episode we’ll discuss the safety and efficacy of acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL; learn more about alternative donor transplantation for severe aplastic anemia and discuss clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation.

Featured Articles:

Acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial
Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT
Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation

S4 Ep423: Auburn WBB Postgame Rutgers